{"url_path":"/sec/cldww/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 ** **Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023094-index.html","accession_number":"0001493152-26-023094","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023094-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":139,"has_tables":true,"body_markdown":"**Item 2.02** **Results of Operations and Financial Condition.**\n\n \n\nOn\nMay 14, 2026, Calidi Biotherapeutics, Inc. (the “Company”) issued a press release announcing certain financial results for\nthe first quarter ended March 31, 2026, and certain other corporate developments. A copy of the press release is incorporated herein\nby reference and is furnished as Exhibit 99.1.\n\n \n\nThe\ninformation under this Item 2.02 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18\nof the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such\nsection, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the\n“Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}